Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

I-MAB - American Depositary Shares (NQ:IMAB)

2.150 -0.140 (-6.11%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about I-MAB - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
36 Stocks Moving In Wednesday's Mid-Day Session
Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Gemini Therapeutics (NASDAQ:GMTX) shares moved upwards by 32.92% to $3.23 during Wednesday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're at the halfway point of the week but there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Week In Review: Shanghai Regor To Discover Metabolic Therapies For Lilly In $1.55 Billion Deal
Regor Therapeutics entered a $1.55 billion research pact with Eli & Lilly to discover therapies for metabolic disorders. Meanwhile, Beijing Avistone Pharma received a $200 million investment led by... 
Via Talk Markets
80 Biggest Movers From Yesterday
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a narrower Q3 loss. Progenity, Inc. (NASDAQ: PROG)... 
Via Benzinga
53 Stocks Moving In Tuesday's Mid-Day Session
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) jumped 65.7% to $1.0691 as the company reported a narrower Q3 loss. Progenity, Inc. (NASDAQ: PROG) shares climbed 35.5% to... 
Via Benzinga
Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million
Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics. 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Valneva (NASDAQ:VALN) shares increased by 24.51% to $50.34 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6... 
Via Benzinga
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
I-Mab Shares Gain On Licensing Pact For Its Human Growth Hormone In China
I-Mab (NASDAQ: IMAB) has collaborated with Jumpcan Pharmaceutical Group to develop, manufacture, and commercialize eftansomatropin alfa (TJ101) in mainland... 
Via Benzinga
MorphoSys Presents Early Felzartamab Data From Autoimmune Kidney Disease Trial
MorphoSys AG (NASDAQ: MOR) presented interim results from the M-PLACE Phase 1b/2a study with felzartamab at the 2021 Annual Meeting of the American Society of... 
Via Benzinga
Week In Review: MicroTech Medical Staging $245 Million HK IPO For Diabetes Products
MicroTech Medical, a Hangzhou company that offers diabetes monitoring and treatment devices, is conducting a Hong Kong IPO that would raise $254 million at the top of the price range. LianBio has filed... 
Via Talk Markets
Topics Initial Public Offering
I-Mab In Talks With Pharma Giants About Partnership, Stake Sale: Bloomberg
A year after I-Mab (NASDAQ: IMAB) made headlines with its $2.9 billion deal licensing a CD47 drug to AbbVie Inc (NYSE: ABBV), the biotech is reportedly... 
Via Benzinga
Why Are I-Mab Shares Trading Higher On Tuesday?
The Center for Drug Evaluation of China National Medical Products Administration has signed off I-Mab's (NASDAQ: IMAB) IND application to initiate a Phase 2... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 70.28% to $9.11 during Tuesday's pre-market session. The company's market cap stands at $24.5... 
Via Benzinga
I-Mab Stock Joins Rank Of Stocks With RS Ratings Over 90
Looking for the best stocks to buy? Focus on those with rising relative strength such as I-Mab stock, which saw a (RS) Rating upgrade to 93. 
Via Investor's Business Daily
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... 
Via Benzinga
I-Mab Stock Flashes Vital Signs With 89 RS Rating
I-Mab stock had its Relative Strength Rating upgraded from 70 to 89 on Wednesday. Is this biopharma stock on your radar? 
Via Investor's Business Daily
10 Biggest Price Target Changes For Wednesday
Rosenblatt raised Ambarella, Inc. (NASDAQ:AMBA) p... 
Via Benzinga
I-MAB (IMAB) Q2 2021 Earnings Call Transcript
IMAB earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares climbed 63.7% to close at $1.22 on Thursday after dropping 12% on Wednesday. Sonnet BioTherapeutics recently... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares moved upwards by 110.49% to $1.57 during Thursday's regular session. Trading volume for Sonnet BioTherapeutics'... 
Via Benzinga
I-Mab Stock Is Trading Lower After Unveiling Mid-Stage Trial Data Of Plonmarlimab In Hospitalized COVID-19 Patients
I-Mab (NASDAQ: IMAB) has announced interim data from its Phase 2/3 study evaluating plonmarlimab (TJM2 or TJ003234) for cytokine release syndrome (CRS) in patients... 
Via Benzinga
Week In Review: Kumquat Signs $2 Billion US-China Deal With Lilly For Novel Immune Drugs
Kumquat Biosciences announced a $2 billion agreement with a Lilly subsidiary to discover small molecule drugs that stimulate tumor-specific immune responses in cancer patients. Lilly will make a $70... 
Via Talk Markets
I-Mab To Start Testing Alzheimer's Candidate In Human Trials
The FDA has signed off I-Mab (NASDAQ: IMAB) Investigational New Drug (IND) application for Protollin, an Alzheimer's candidate. Brigham and Women's... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Infinity Pharmaceuticals (NASDAQ:INFI) shares moved upwards by 45.98% to $2.22 during Wednesday's regular session. As of 12:30 EST, this security is trading at... 
Via Benzinga
I-Mab Stock Moves Higher As IND For Mid-Stage Efineptakin Cancer Trial Accepted By China
The National Medical Products Administration (NMPA) of China has signed off I-Mab's (NASDAQ: IMAB) IND application to initiate a Phase 2 trial of efineptakin... 
Via Benzinga
62 Biggest Movers From Yesterday
Gainers Flora Growth Corp. (NASDAQ: FLGC) surged 63.1% to close at $8.27. The Miami-based cannabis producer confirmed Tuesday it has signed a non-binding letter of intent to... 
Via Benzinga
Topics Cannabis
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares jumped 59.9% to $2.43. Infinity Pharmaceuticals shares tumbled over 31% on Tuesday after the company highlighted the... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.